Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report

详细信息    查看全文

• 作者：Luis Daverede ; Christy Ralph ; Satinder P Jagdev…
• 关键词：Castrate ; resistant prostate cancer ; Chemotherapy ; Complete response ; PSA
• 刊名：Journal of Medical Case Reports
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：8
• 期：1
• 全文大小：378 KB
• 参考文献：1. Haas, GP, Delongchamps, N, Brawley, OW, Wang, CY, de la Roza, G (2008) The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 15: pp. 3866-3871
  Prostate cancer statistics.
  2. Tannock, IF, de Wit, R, Berry, WR, Horti, J, Pluzanska, A, Chi, KN, Oudard, S, Théodore, C, James, ND, Turesson, I, Rosenthal, MA, Eisenberger, MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Eng J Med 351: pp. 1502-1512 CrossRef
  3. de Bono, JS, Logothetis, CJ, Molina, A, Fizazi, K, North, S, Chu, L, Chi, KN, Jones, RJ, Goodman, OB, Saad, F, Staffurth, JN, Mainwaring, P, Harland, S, Flaig, TW, Hutson, TE, Cheng, T, Patterson, H, Hainsworth, JD, Ryan, CJ, Sternberg, CN, Ellard, SL, Fléchon, A, Saleh, M, Scholz, M, Efstathiou, E, Zivi, A, Bianchini, D, Loriot, Y, Chieffo, N, Kheoh, T (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: pp. 1995-2005 CrossRef
  4. Scher, HI, Fizazi, K, Saad, F, Taplin, ME, Sternberg, CN, Miller, K, de Wit, R, Mulders, P, Chi, KN, Shore, ND, Armstrong, AJ, Flaig, TW, Fléchon, A, Mainwaring, P, Fleming, M, Hainsworth, JD, Hirmand, M, Selby, B, Seely, L, de Bono, JS (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367: pp. 1187-1197 CrossRef
  5. Tannock, IF, Fizazi, K, Ivanov, S, Karlsson, CT, Fléchon, A, Skoneczna, I, Orlandi, F, Gravis, G, Matveev, V, Bavbek, S, Gil, T, Viana, L, Arén, O, Karyakin, O, Elliott, T, Birtle, A, Magherini, E, Hatteville, L, Petrylak, D, Tombal, B, Rosenthal, M (2013) Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 4: pp. 760-768 CrossRef
  6. Eisenhauer, EA, Therasse, P, Bogaerts, J, Schwartz, LH, Sargent, D, Ford, R, Dancey, J, Arbuck, S, Gwyther, S, Mooney, M, Rubinstein, L, Shankar, L, Dodd, L, Kaplan, R, Lacombe, D, Verweij, J (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: pp. 228-247 CrossRef
  7. Hanninen, M, Venner, P, North, S (2009) A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Can Urol Assoc J 3: pp. 369-374
  8. Goc, A, Kochuparambil, ST, Al-Husein, B, Al-Azayzih, A, Mohammad, S, Somanath, PR (2012) Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis. BMC Cancer 12: pp. 409 CrossRef
  9. Dale, KM, Coleman, CI, Henyan, NN, Kluger, J, White, CM (2006) Statins and cancer risk: a meta-analysis. JAMA 295: pp. 74-80 CrossRef
  10. Choe, KS, Cowan, JE, Chan, JM, Carroll, PR, D'Amico, AV, Liauw, SL (2012) Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 30: pp. 3540-3544 CrossRef
  11. Kundranda, MN, Muslimani, A, Daw, HA, Spiro, TP (2007) Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal. Clin Genitourin Cancer 5: pp. 401-402 CrossRef
  12. Bissada, NK, Kaczmarek, AT (1995) Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. J Urol 153: pp. 1944-1945 CrossRef
  
• 刊物主题：Medicine/Public Health, general; General Practice / Family Medicine; Public Health; Primary Care Medicine;
• 出版者：BioMed Central
• ISSN：1752-1947

文摘

Introduction Although treatment options for men with metastatic castrate-resistant prostate cancer have improved in recent years, the outlook for patients remains poor, with overall survival in the region of 2?years. Response rates with chemotherapy are modest and disease progression is usually observed within months of stopping treatment. Case presentation We present a case of a 72-year-old White man of British origin with metastatic castrate-resistant prostate cancer with bulky lymphadenopathy and a serum prostate-specific antigen of 295μg/L. He received treatment with docetaxel chemotherapy plus prednisolone, but received just 3?cycles before treatment was stopped due to toxicity and lack of response (prostate-specific antigen was 276μg/L 4 weeks after the last dose and there was a confirmed stable appearance on computed tomography scan). Unexpectedly, at follow-up 4?months later, the patient was clinically better; his prostate-specific antigen had dramatically improved to 4.1μg/L and a re-staging computed tomography scan revealed complete resolution of his bulky lymphadenopathy. At the time, he was receiving a luteinising hormone-releasing hormone analogue but no other disease-modulating treatment. He remains well and asymptomatic, with his most recent serum prostate-specific antigen measuring 0.14μg/L, 18?months after last receiving chemotherapy. Conclusion We report a case of complete and durable regression of metastatic castrate-resistant prostate cancer following palliative chemotherapy which, to the best of our knowledge, has not previously been reported in the literature.